Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.
Curr Treat Options Oncol. 2024 Apr;25(4):465-495. doi: 10.1007/s11864-023-01175-z. Epub 2024 Feb 19.
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
心脏毒性已成为癌症治疗领域中各种治疗靶点引发的严重后果，其中包括化疗、放疗和靶向治疗。癌症药物诱导的心脏毒性（CDIC）和放射性心脏毒性（CRIC）的日益重要性需要立即引起关注。本文详细揭示了癌症治疗如何导致心脏毒性，以及患者特定风险如何加剧这种毒性。具体而言，蒽环类药物、烷化剂和酪氨酸激酶抑制剂等药物以及高血压和糖尿病等因素会带来风险。对氧化应激和拓扑异构酶-II-B 抑制的机制见解至关重要，而心脏生物标志物则显示出早期损伤。及时干预和及时治疗，特别是使用地拉佐嗪和β受体阻滞剂等特定药物，对于 CDIC 的积极管理至关重要。
